Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.35 |
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2315228 | 0.88 | KCNH2 (0.37) | DGAT1KCNH2NR1H3NR1H2LOXL2 | |
| SCHEMBL2316599 | 0.82 | NAMPT (0.32) | KCNH2NR1H3NR1H2 | |
| SCHEMBL2320132 | 0.80 | PIK3CB (0.38) | DGAT1KCNH2LOXL2 | |
| SCHEMBL2319988 | 0.80 | KCNH2 (0.35) | KCNH2NR1H2 | |
| SCHEMBL2317935 | 0.79 | PRKDC (0.40) | KCNH2NR1H2 | |
| SCHEMBL2316450 | 0.76 | JAK2 (0.36) | DGAT1KCNH2 | |
| SCHEMBL2317057 | 0.70 | MAPT (0.35) | DGAT1 | |
| SCHEMBL2319842 | 0.69 | SYK (0.40) | KCNH2NR1H3NR1H2RXRALOXL2 | |
| SCHEMBL2315378 | 0.69 | TDP1 (0.36) | DGAT1 | |
| SCHEMBL2317105 | 0.69 | CHEK1 (0.34) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | DGAT1 2419/4885KCNH2 738/4885NR1H3 698/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | DGAT1 2419/4885KCNH2 738/4885NR1H3 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.